A Phase 1/2 study to assess the safety, immunogenicity and recommended dose of DS-5670a (COVID-19 Vaccine) in Japanese healthy adults and elderly subjects

Inoguchi Akihiro0 个研究点目标入组 152 人开始时间: 2021年3月10日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Japanese
•2) Healthy adults aged >=20 and <65 years, or healthy elderly aged >=65 and <75 years (at the time of informed consent)
•3) Body Mass Index (BMI) is >=17.5 and <30.0 kg/m^2 (at screening )
•4) Subjects who can follow the compliance requirements during clinical trials, undergo medical examinations and tests specified by the protocol, and report symptoms, etc.

•1) Having a history of anaphylaxis or severe allergies due to food, cosmetics, medicines, or vaccination.
•2) Having alcohol or drug dependence.
•3) Having a history of immunodeficiency or having a close relative with congenital immunodeficiency.
•4) Having a history of SARS-CoV-2 infection.
•5) Having fever of >=39.0 C or symptoms of suspected allergies such as systemic rash within 2 days after past vaccination.

发起方

Inoguchi Akihiro